awmsg logo



blinatumomab (Blincyto®)


Reference No. 589

Publication date:
27/07/2016


Appraisal information

blinatumomab (Blincyto®) 38.5 microgram/vial powder for concentrate and solution for solution for infusion


Company: Amgen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1916
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Blinatumomab (Blincyto®) is recommended as an option for use within NHS Wales for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download